Lixte Biotechnology Holdings, Inc.

MUN:8640 Stock Report

Market Cap: €4.6m

Lixte Biotechnology Holdings Balance Sheet Health

Financial Health criteria checks 4/6

Lixte Biotechnology Holdings has a total shareholder equity of $1.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.7M and $329.0K respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$1.64m
EquityUS$1.37m
Total liabilitiesUS$328.96k
Total assetsUS$1.70m

Recent financial health updates

Recent updates

Financial Position Analysis

Short Term Liabilities: 8640's short term assets ($1.7M) exceed its short term liabilities ($329.0K).

Long Term Liabilities: 8640 has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 8640 is debt free.

Reducing Debt: 8640 had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 8640 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 8640 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 19.5% each year


Discover healthy companies